Moderna (MRNA) Change in Cash (2018 - 2026)
Moderna (MRNA) posted quarterly Change in Cash of -$185.0 million for Q2 2026, up 46.38% year-over-year from -$126.4 million in Q2 2025, and up 73.11% on a QoQ basis from -$688.0 million in Q1 2026.
Moderna (MRNA) Change in Cash (2018 - 2026) Analysis & Trends
Moderna has reported Change in Cash for 9 years, with the latest figure at -$185.0 million in Q2 2026.
- Change in Cash for Q2 2026 came in at -$185.0 million, up 46.38% year-over-year; the trailing twelve-month figure through Jun 2026 was $443.0 million (up 136.95% YoY), and the FY2025 annual result was $668.0 million, up 166.87% from the prior year.
- Change in Cash grew to -$185.0 million in Q2 2026, from -$688.0 million in the prior quarter.
- Over five years, Change in Cash peaked at $1.5 billion in Q4 2025 and troughed at -$2.2 billion in Q2 2022.
- A 5-year average of -$285.3 million and a median of -$166.0 million in 2025 frame the typical range for Change in Cash.
- The widest annual swing landed in 2022, when Change in Cash slumped 1450.93%; it then soared 1228.0% in 2024.
- A 5-year view of Change in Cash shows it stood at $176.0 million in 2022, then plunged by 114.2% to -$25.0 million in 2023, then soared by 1228.0% to $282.0 million in 2024, then surged by 418.79% to $1.5 billion in 2025, then sank by 112.65% to -$185.0 million in 2026.
- Per Business Quant data, the three most recent Change in Cash figures were -$185.0 million in Q2 2026, -$688.0 million in Q1 2026, and $1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -185.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -185.00 Mn |
| Mar 31, 2026 | -688.00 Mn |
| Dec 31, 2025 | 1.46 Bn |
| Sep 30, 2025 | -147.00 Mn |
| Jun 30, 2025 | -345.00 Mn |
| Mar 31, 2025 | -303.00 Mn |
| Dec 31, 2024 | 282.00 Mn |
| Sep 30, 2024 | -833.00 Mn |
| Jun 30, 2024 | 409.00 Mn |
| Mar 31, 2024 | -857.00 Mn |
| Dec 31, 2023 | -25.00 Mn |
| Sep 30, 2023 | -869.00 Mn |
| Jun 30, 2023 | 361.00 Mn |
| Mar 31, 2023 | 244.00 Mn |
| Dec 31, 2022 | 176.00 Mn |
| Sep 30, 2022 | 156.00 Mn |
| Jun 30, 2022 | -2.18 Bn |
| Mar 31, 2022 | -1.80 Bn |
| Dec 31, 2021 | 1.30 Bn |
| Sep 30, 2021 | -53.00 Mn |